000056333 001__ 56333
000056333 005__ 20200221144253.0
000056333 0247_ $$2doi$$a10.3390/molecules21060783
000056333 0248_ $$2sideral$$a95669
000056333 037__ $$aART-2016-95669
000056333 041__ $$aeng
000056333 100__ $$aZavala-Mendoza, D.
000056333 245__ $$aAntispasmodic effects and action mechanism of essential oil of Chrysactinia mexicana A. Gray on rabbit ileum
000056333 260__ $$c2016
000056333 5060_ $$aAccess copy available to the general public$$fUnrestricted
000056333 5203_ $$aThe Chrysactinia mexicana A. Gray (C. mexicana) plant is used in folk medicine to treat fever and rheumatism; it is used as a diuretic, antispasmodic; and it is used for its aphrodisiac properties. This study investigates the effects of the essential oil of C. mexicana (EOCM) on the contractility of rabbit ileum and the mechanisms of action involved. Muscle contractility studies in vitro in an organ bath to evaluate the response to EOCM were performed in the rabbit ileum. EOCM (1–100 µg·mL-1) reduced the amplitude and area under the curve of spontaneous contractions of the ileum. The contractions induced by carbachol 1 µM, potassium chloride (KCl) 60 mM or Bay K8644 1 µM were reduced by EOCM (30 µg·mL-1). Apamin 1 µM and charybdotoxin 0.01 µM decreased the inhibition induced by EOCM. The d-cAMP 1 µM decreased the inhibition induced by EOCM. l-NNA 10 µM, Rp-8-Br-PET-cGMPS 1 µM, d, l-propargylglycine 2 mM, or aminooxyacetic acid hemihydrochloride 2 mM did not modify the EOCM effect. In conclusion, EOCM induces an antispasmodic effect and could be used in the treatment of intestinal spasms or diarrhea processes. This effect would be mediated by Ca2+, Ca2+-activated K+ channels and cAMP.
000056333 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B61
000056333 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000056333 590__ $$a2.861$$b2016
000056333 591__ $$aCHEMISTRY, ORGANIC$$b17 / 59 = 0.288$$c2016$$dQ2$$eT1
000056333 592__ $$a0.824$$b2016
000056333 593__ $$aAnalytical Chemistry$$c2016$$dQ1
000056333 593__ $$aPharmaceutical Science$$c2016$$dQ1
000056333 593__ $$aChemistry (miscellaneous)$$c2016$$dQ1
000056333 593__ $$aOrganic Chemistry$$c2016$$dQ2
000056333 593__ $$aPhysical and Theoretical Chemistry$$c2016$$dQ2
000056333 593__ $$aDrug Discovery$$c2016$$dQ2
000056333 593__ $$aMedicine (miscellaneous)$$c2016$$dQ2
000056333 593__ $$aMolecular Medicine$$c2016$$dQ3
000056333 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000056333 700__ $$0(orcid)0000-0002-5306-9365$$aGrasa, L.$$uUniversidad de Zaragoza
000056333 700__ $$aZavala-Sánchez, M.A.
000056333 700__ $$aPérez-Gutiérrez, S.
000056333 700__ $$0(orcid)0000-0002-3917-4740$$aMurillo, M.D.
000056333 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000056333 773__ $$g21, 6 (2016), [12 pp.]$$pMolecules$$tMolecules$$x1420-3049
000056333 8564_ $$s1479488$$uhttps://zaguan.unizar.es/record/56333/files/texto_completo.pdf$$yVersión publicada
000056333 8564_ $$s103799$$uhttps://zaguan.unizar.es/record/56333/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000056333 909CO $$ooai:zaguan.unizar.es:56333$$particulos$$pdriver
000056333 951__ $$a2020-02-21-13:28:29
000056333 980__ $$aARTICLE